BS_B7QS4DHK
Schwannoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Schwannoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Schwannoma
- overall_survival_months
- 249.96714848883047
- age_years
- 4.304
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VJAC9H58 | Schwannoma | — | 0.960 |
| 2 | BS_479S95Q6 | Schwannoma | — | 0.937 |
| 3 | BS_Y3G1X98S | Meningioma | — | 0.937 |
| 4 | BS_2W3NC4K1 | Neurofibroma | — | 0.934 |
| 5 | BS_CS66RYDA | Schwannoma | — | 0.921 |
| 6 | BS_1SVVER1H | Schwannoma | — | 0.921 |
| 7 | BS_THSPSG2Z | Meningioma | — | 0.920 |
| 8 | BS_9HA238XS | Neurofibroma | — | 0.919 |
| 9 | BS_893A91ZM | Neurofibroma | — | 0.913 |
| 10 | MDT-AP-2021 | Med | Medulloblastoma | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.767 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.687 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.585 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.551 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| COAGULATION | 0.497 | Binimetinib | — uncovered |
| COMPLEMENT | 0.486 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.476 | Inavolisib | — uncovered |
| APOPTOSIS | 0.437 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.432 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.394 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.393 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.374 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.297 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.287 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.262 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.259 | Inavolisib | — uncovered |
| HYPOXIA | 0.189 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.175 | Inavolisib | — uncovered |